Divalproex
Depakote
Mood Stabilizer
NADAC/unit
$0.0553
No Shortage
Tier 1: 159.9%
21 Manufacturers
56 ANDAs
Divalproex sodium extended-release tablets are indicated for: • Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features ( 1.1 ) • Monotherapy....
vs. brand Depakote: Generic saves up to 99% per unit
Active Shortages
2025-04-28 Discontinuation of manufacture of drug based on business decision., Upsher-Smith Laboratories, LLC
2025-04-28 Discontinuation of manufacture of drug based on business decision., Upsher-Smith Laboratories, LLC
2025-04-28 Discontinuation of manufacture of drug based on business decision., Upsher-Smith Laboratories, LLC
2025-04-28 Discontinuation of manufacture of drug based on business decision., Upsher-Smith Laboratories, LLC
2025-04-28 Discontinuation of manufacture of drug based on business decision., Upsher-Smith Laboratories, LLC
Market Intelligence
2024-04-03 Class II Recall: Amneal Pharmaceuticals of New York, LLC
Generic Manufacturers
ABBVIE INCAJANTA PHARMA LTDALEMBIC PHARMACEUTICALS LTDAMNEAL PHARMACEUTICALSANNORA PHARMA PRIVATE LTDAUROBINDO PHARMA LIMITEDAUROBINDO PHARMA LTDCHARTWELL RX SCIENCES LLCDOCTOR REDDYS LABORATORIES LTDDR REDDYS LABORATORIES LTDINVATECH PHARMA SOLUTIONS LLCLUPIN LTDMANKIND PHARMA LTDMYLAN PHARMACEUTICALS INCORBION PHARMACEUTICALS PRIVATE LTDPRINSTON PHARMACEUTICAL INCSCIEGEN PHARMACEUTICALS INCSUN PHARMACEUTICAL INDUSTRIES LTDUNICHEM LABORATORIES LIMITEDUNICHEM LABORATORIES LTDUPSHER SMITH LABORATORIES LLCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.